Genetic risk factors for drug-induced liver injury in rheumatoid arthritis patients using low-dose methotrexate

2013 ◽  
Vol 14 (1) ◽  
pp. 63-73 ◽  
Author(s):  
Cristina Lucía Dávila-Fajardo ◽  
Jesse J Swen ◽  
José Cabeza Barrera ◽  
Henk-Jan Guchelaar
Keyword(s):  
Rheumatoid Arthritis ◽  
Risk Factors ◽  
Liver Injury ◽  
Genetic Risk ◽  
Low Dose ◽  
Genetic Risk Factors ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Dose Methotrexate

scholarly journals Genetic Risk Factors in Drug‐Induced Liver Injury Due to Isoniazid‐Containing Antituberculosis Drug Regimens

2020 ◽  
Author(s):  
Paola Nicoletti ◽  
Harshad Devarbhavi ◽  
Ashish Goel ◽  
Radha Venkatesan ◽  
Chundamannil E. Eapen ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Injury ◽  
Genetic Risk ◽  
Genetic Risk Factors ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Drug Regimens

High-dose methotrexate-induced reversible grade 4 hyperbilirubinaemia and transaminitis in an adolescent with Burkitt Leukaemia

2021 ◽  
Vol 14 (1) ◽  
pp. e237512
Author(s):  
Sanjeev Khera ◽  
Randhir Ranjan ◽  
Sateesh Ramachandran ◽  
Ajay Beriwal
Keyword(s):  
Liver Injury ◽  
Clinical Significance ◽  
Short Latency ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Drug Induced ◽  
Common Cause ◽  
Drug Induced Liver Injury ◽  
Dose Methotrexate

Symptomatic drug-induced liver injury (DILI) is an uncommon problem. Direct DILI is dose-related, predictable with short latency (hour to days) and is generally associated with transient and reversible transaminitis without jaundice. Antimetabolites including methotrexate are a common cause for direct DILI. Hepatotoxicity associated with high-dose methotrexate (HD-MTX) is generally transient and includes reversible elevation of transaminase in up to 60% and associated hyperbilirubinaemia (≤grade 2) in 25% of courses and therefore is of no clinical significance. Severe grades of DILI with HD-MTX (grade ≥4) are extremely rare. We describe an adolescent with Burkitt leukaemia who had reversible grade 4 DILI including hyperbilirubinaemia postfirst course of HD-MTX. Rechallenge with two-third dose of HD-MTX in subsequent chemotherapeutic cycle did not cause recurrence of DILI.

Sign in / Sign up

Export Citation Format

Share Document